Enterprise Value

7.158B

Cash

77.55M

Avg Qtr Burn

-14.78M

Short % of Float

0.10%

Insider Ownership

0.00%

Institutional Own.

1.09%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
REVASCOR® (Rexlemestrocel) Details
Heart disease, Hypoplastic Left Heart Syndrome

BLA

Acceptance for review

RYONCIL™ (Remestemcel-L) Details
Acute graft-versus host disease

BLA

Resubmission

REVASCOR® (Rexlemestrocel) Details
Heart disease, Heart failure

BLA

FDA meeting

Rexlemestrocel Details
Chronic lower back pain

Phase 3

Update

Remestemcel-L Details
Inflammatory bowel disease, Bowel disorder, Crohns disease

Failed

Discontinued

Failed

Discontinued